{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007233","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.939052+00:00","generated_at":"2026-06-22T04:53:58.349319+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Anika Q3 revenue $40.3M (+2% YoY); net loss ($4.2M); Cingal Phase III hits endpoint","bullets":["Revenue $40.3M (+2% YoY); OA Pain Mgmt $25.7M (-2%), Joint Preservation $11.8M (+6%), Non-Ortho $2.8M (+27%).","Net loss ($4.2M) vs net income $0.6M prior year; adjusted net loss ($0.7M); adjusted EBITDA $4.1M vs $5.7M.","Cingal Phase III (Cingal 19-01) achieved primary endpoint — superiority over steroid alone at 26 weeks; FDA meeting planned.","Hyalofast pivotal Phase III 96% enrolled (193 patients); full enrollment expected early 2023; PMA filing on track for 2025.","FY2022 guidance: overall revenue toward upper end of low to mid single-digit growth; OA Pain Mgmt now expected up mid to upper single-digit %."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007233","json":"https://secwatch.observer/filing/0001171843-22-007233.json","markdown":"https://secwatch.observer/filing/0001171843-22-007233.md","text":"https://secwatch.observer/filing/0001171843-22-007233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184322007233/0001171843-22-007233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184322007233/f8k_110822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:53:58.349319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f4bbd4ed541d78bd1a279bae48d9ba4adb568e5b","claim":"Anika Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $40.3 million, net income ($4.2) million, or ($0.29) per share, EPS ($0.29) per share.","evidence_excerpt":"orthopedics, today reported financial results for its third quarter ended September 30, 2022. Third Quarter 2022 Financial Summary Revenue in the third quarter of 2022 was $40.3 million, up 2% compared with $39.5 million in the third quarter of 2021. OA Pain Management 1 revenue of $25.7 million, down 2% Joint Preservation and Restoration revenue of $11.8","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184322007233/0001171843-22-007233-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$40.3 million"},{"label":"Net income","value":"($4.2) million, or ($0.29) per share"},{"label":"EPS","value":"($0.29) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}